JP2017537124A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537124A5
JP2017537124A5 JP2017530656A JP2017530656A JP2017537124A5 JP 2017537124 A5 JP2017537124 A5 JP 2017537124A5 JP 2017530656 A JP2017530656 A JP 2017530656A JP 2017530656 A JP2017530656 A JP 2017530656A JP 2017537124 A5 JP2017537124 A5 JP 2017537124A5
Authority
JP
Japan
Prior art keywords
breast cancer
composition
use according
patient
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017530656A
Other languages
English (en)
Japanese (ja)
Other versions
JP7113619B2 (ja
JP2017537124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/064491 external-priority patent/WO2016094402A1/en
Publication of JP2017537124A publication Critical patent/JP2017537124A/ja
Publication of JP2017537124A5 publication Critical patent/JP2017537124A5/ja
Application granted granted Critical
Publication of JP7113619B2 publication Critical patent/JP7113619B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017530656A 2014-12-09 2015-12-08 リポソーマルイリノテカンによる乳がんの治療 Expired - Fee Related JP7113619B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089685P 2014-12-09 2014-12-09
US62/089,685 2014-12-09
PCT/US2015/064491 WO2016094402A1 (en) 2014-12-09 2015-12-08 Treatment of breast cancer with liposomal irinotecan

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020022400A Division JP2020073601A (ja) 2014-12-09 2020-02-13 リポソーマルイリノテカンによる乳がんの治療

Publications (3)

Publication Number Publication Date
JP2017537124A JP2017537124A (ja) 2017-12-14
JP2017537124A5 true JP2017537124A5 (enExample) 2019-01-24
JP7113619B2 JP7113619B2 (ja) 2022-08-05

Family

ID=54979964

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017530656A Expired - Fee Related JP7113619B2 (ja) 2014-12-09 2015-12-08 リポソーマルイリノテカンによる乳がんの治療
JP2020022400A Withdrawn JP2020073601A (ja) 2014-12-09 2020-02-13 リポソーマルイリノテカンによる乳がんの治療
JP2022045463A Pending JP2022079545A (ja) 2014-12-09 2022-03-22 リポソーマルイリノテカンによる乳がんの治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020022400A Withdrawn JP2020073601A (ja) 2014-12-09 2020-02-13 リポソーマルイリノテカンによる乳がんの治療
JP2022045463A Pending JP2022079545A (ja) 2014-12-09 2022-03-22 リポソーマルイリノテカンによる乳がんの治療

Country Status (6)

Country Link
US (2) US20160346272A1 (enExample)
EP (1) EP3229802A1 (enExample)
JP (3) JP7113619B2 (enExample)
AU (1) AU2015360761B2 (enExample)
HK (1) HK1245133A1 (enExample)
WO (1) WO2016094402A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) * 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
ES3036518T3 (en) 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
JP2021534091A (ja) * 2018-08-05 2021-12-09 ダ・ヴォルテッラ 抗がん剤の有効性を改善する方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI283575B (en) * 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
EP2004175A4 (en) * 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE
WO2012012454A1 (en) * 2010-07-19 2012-01-26 Bipar Sciences, Inc. Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan
AU2013202947B2 (en) * 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
WO2014113167A1 (en) 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents
SG10201913073YA (en) * 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) * 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
ES3036518T3 (en) * 2015-10-16 2025-09-19 Ipsen Biopharm Ltd Stabilizing camptothecin pharmaceutical compositions

Similar Documents

Publication Publication Date Title
ES2424476T3 (es) Nanopartículas cargadas con fármaco antitumoral quimioterápico
JP2015523355A5 (enExample)
JP2019515908A5 (enExample)
WO2011066684A1 (zh) 伊立替康或盐酸伊立替康脂质体及其制备方法
JP2018184465A5 (enExample)
ES2956013T3 (es) Formulación de equinomicina, método de producción y método de uso de la misma
JP2025087753A (ja) メトピマジンの新規多形形態
JP7015237B2 (ja) 腫瘍の成長を抑制する方法
JP2019516693A5 (enExample)
EP3532067A1 (en) Liposomal formulation for use in the treatment of cancer
JP2012522730A (ja) 多糖リポソーム、その調製法及びその使用
JP2017520620A5 (enExample)
Krasnopolskii et al. Technologies and perspectives of liposomal drug application in clinical practice
JP2021178839A (ja) 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法
WO2001083020A1 (en) Antineoplastic platinum therapeutic method and composition
CN1917885A (zh) 抗癌疗法
CN117897140A (zh) 用于制备脂质体制剂的方法
EP3687498A1 (en) Parenteral formulation comprising siponimod
WO2016008289A1 (zh) 一种盐酸伊立替康纳米脂束制剂及其制备方法
US11096893B2 (en) Glucose sensitive compositions for drug delivery
JP6080837B2 (ja) 療法的治療
CN109419773B (zh) 复合纳米脂质给药系统及其对妇科肿瘤的治疗作用
WO2024031005A2 (en) Treating cancer with long-acting topoisomerase i inhibitor
CN108135878A (zh) 卡巴他赛及其治疗癌症的用途
CN105769849B (zh) 一种治疗卵巢癌的药物组合物